Soligenix, Inc. (SNGX) - Q1 2026 Filing Summary
Business Context and Reporting Period
This summary covers the Form 10-Q for the quarterly period ended March 31, 2026. Soligenix, Inc. is a biopharmaceutical company operating two segments: Specialized BioTherapeutics (focusing on synthetic hypericin and dusquetide for rare diseases) and Public Health Solutions (focusing on vaccine candidates like RiVax and filovirus vaccines). The company is currently in a pre-revenue stage, relying on government grants and equity financing.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenues | $0 | $0 |
| Net Loss | $(2,824,965) | $(2,951,268) |
| Net Loss Per Share (Basic/Diluted) | $(0.28) | $(0.97) |
| Operating Expenses | $2,884,838 | $3,026,508 |
| Cash and Cash Equivalents (End of Period) | $6,029,430 | $7,297,171 |
| Working Capital | $2,945,938 | $5,149,732 (Dec 31, 2025) |
| Shareholders' Equity | $3,089,905 | $3,897,933 (Mar 31, 2025) |
| Accumulated Deficit | $(247,876,097) | $(236,922,020) (Mar 31, 2025) |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by $126,303 (4.3%) compared to Q1 2025, primarily driven by a $159,380 reduction in Research and Development (R&D) expenses.
- R&D Expenses: Decreased to $1.78 million from $1.94 million. The reduction was due to lower third-party manufacturing costs and the completion of the Phase 2 study for SGX945 (Behçet's Disease), partially offset by increased patient fees for the confirmatory Phase 3 CTCL trial.
- General and Administrative (G&A): Increased slightly by $17,710 to $1.10 million.
- Cash Position: Cash decreased by $1.91 million during the quarter due to operating cash outflows of $2.36 million, partially offset by $509,277 in proceeds from At-The-Market (ATM) stock sales.
- Equity Dilution: The company issued 423,799 shares via the Rodman Sales Agreement and 8,340 shares to vendors during the quarter.
Guidance, Outlook, and Risks
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. While cash runway is projected into 2027 based on current budgets, the company does not have sufficient cash to fund operations for the next 12 months without additional financing.
- Capital Strategy: The company plans to secure additional capital through public/private equity offerings, government grants, and ATM sales. Approximately $0.8 million of capacity remains under the current Rodman Sales Agreement.
- Clinical Trial Update (Critical): The Data Monitoring Committee recommended halting the FLASH2 Phase 3 trial for HyBryte (CTCL treatment) for futility following an interim efficacy analysis in April 2026. The company is analyzing data to determine the cause of the failure.
- Nasdaq Listing Risk: Shareholders' equity declined to $3.1 million. The company must maintain at least $2.5 million in equity to comply with Nasdaq listing standards. Continued losses could trigger a delisting notification if equity falls below this threshold.
- Future R&D Spend: The company expects R&D expenditures of approximately $2.0 million over the next 12 months, with no anticipated grant reimbursements to offset these costs in the Specialized BioTherapeutics segment.
Investor Verification Checklist
- Financing Timeline: Verify the status of new capital raises or government grant applications required to bridge the 12-month liquidity gap.
- FLASH2 Trial Analysis: Monitor the company's analysis of the halted Phase 3 CTCL trial to understand the path forward for HyBryte.
- Nasdaq Compliance: Track quarterly shareholders' equity to ensure it remains above the $2.5 million minimum listing requirement.
- ATM Capacity: Confirm the utilization of the remaining $0.8 million capacity under the Rodman Sales Agreement and the pricing of recent issuances.
- Contractual Obligations: Review the $5 million milestone payment obligation to Hy Biopharma contingent on FDA approval of HyBryte.